A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
Phase of Trial: Phase I/II
Latest Information Update: 06 Dec 2018
At a glance
- Drugs ALN-HBV02 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Vir Biotechnology
- 06 Dec 2018 According to an Alnylam Pharmaceuticals media release, data read out from this trial is expected in 2019.
- 26 Nov 2018 Status changed from not yet recruiting to recruiting.
- 21 Sep 2018 New trial record